Hemostemix Inc. (CVE:HEM – Get Free Report)’s stock price fell 22.9% during trading on Friday . The company traded as low as C$0.18 and last traded at C$0.19. 504,239 shares traded hands during trading, a decline of 5% from the average session volume of 530,580 shares. The stock had previously closed at C$0.24.
Hemostemix Trading Down 22.9 %
The firm has a market capitalization of C$26.96 million, a PE ratio of -5.39 and a beta of 0.20. The stock’s 50-day moving average price is C$0.19 and its 200 day moving average price is C$0.11. The company has a debt-to-equity ratio of -55.07, a current ratio of 0.04 and a quick ratio of 0.48.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Articles
- Five stocks we like better than Hemostemix
- 3 Fintech Stocks With Good 2021 Prospects
- Vertiv Stock Under Pressure: Is Opportunity Knocking?
- Canada Bond Market Holiday: How to Invest and Trade
- MicroStrategy’s 8% Preferred Stock: What Investors Should Know
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Biotechs on the Brink: 2 Stocks With Huge Potential
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
